Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency

Gene Therapy

Volumn 15, Issue 19, 2008, Pages 1321-1329

  Yoshikawa, T ^a   Niwa, T ^a   Mizuguchi, H ^b   Okada, N ^a   Nakagawa, S ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; PROTEIN BCL X;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; FEMALE; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; LONGEVITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION; TUMOR IMMUNITY; VACCINE PRODUCTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL SURVIVAL; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENETIC ENGINEERING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SKIN NEOPLASMS; TRANSDUCTION, GENETIC;

EID: 52049086444     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.85     Document Type: Article

References (37)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
2. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005; 5: 617-628.
3. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138-147.
4. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003; 21: 873-886.
5. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000; 164: 3095-3101.
6. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196: 1091-1097.
7. Nestle FO. A new lease on life for dendritic cell vaccines? Nat Biotechnol 2006; 24: 1483-1484.
8. Chen M, Huang L, Shabier Z, Wang J. Regulation of the lifespan in dendritic cell subsets. Mol Immunol 2007; 44: 2558-2565.
9. Park Y, Lee SW, Sung YC. Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3′-OH kinase pathway. J Immunol 2002; 168: 5-8.
10. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M et al TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000; 191: 495-502.
11. Miga AJ, Masters SR, Durell BG, Gonzalez M, Jenkins MK, Maliszewski C et al. Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. Eur J Immunol 2001; 31: 959-965.
12. Nopora A, Brocker T. Bcl-2 controls dendritic cell longevity in vivo. J Immunol 2002; 169: 3006-3014.
13. Hon H, Rucker III EB, Hennighausen L, Jacob J. bcl-xL is critical for dendritic cell survival in vivo. J Immunol 2004; 173: 4425-4432.
14. Hou WS, Van Parijs L. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol 2004; 5: 583-589.
15. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
16. Okada N, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Saito T et al Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Biophys Res Commun 2001; 282: 173-179.
17. Okada N, Masunaga Y, Okada Y, Iiyama S, Mori N, Tsuda T et al. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther 2003; 10: 421-431.
18. Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61: 7913-7919.
19. Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y et al. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA 2002; 99: 17107-17112.
20. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308.
21. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
22. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403: 98-103.
23. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med 1997; 185: 2133-2141.
24. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 2002; 100: 1734-1741.
25. Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol 2006; 24: 1581-1590.
26. Mizuguchi H, Funakoshi N, Hosono T, Sakurai F, Kawabata K, Yamaguchi T et al. Rapid construction of small interfering RNA-expressing adenoviral vectors on the basis of direct cloning of short hairpin RNA-coding DNAs. Hum Gene Ther 2007; 18: 74-80.
27. Kang TH, Lee JH, Noh KH, Han HD, Shin BC, Choi EY et al. Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer 2007; 120: 1696-1703.
28. Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003; 171: 2970-2976.
29. Kim JH, Chen J, Majumder N, Lin H, Falo Jr LD, You Z. 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity. Gene Therapy 2005; 12: 1517-1525.
30. Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG. Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 2002; 86: 1529-1533.
31. Okada N, Masunaga Y, Okada Y, Mizuguchi H, Iiyama S, Mori N et al. Dendritic cells transduced with gp100 gene by RGD fibermutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Therapy 2003; 10: 1891-1902.
32. Okada N, Mori N, Koretomo R, Okada Y, Nakayama T, Yoshie O et al. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Therapy 2005; 12: 129-139.
33. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol 1994; 153: 4925-4933.
34. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N et al An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
35. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998; 9: 2577-2583.
36. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Therapy 2001; 8: 730-735.
37. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/ E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999; 10: 2013-2017.